Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasms × Random Allocation × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 313 Trastuzumab 298 Paclitaxel 263 Docetaxel 237 Capecitabine 207 Letrozole 188 Doxorubicin 159 Carboplatin 156 Radiotherapy 140 Tamoxifen 138 Fulvestrant 124 Epirubicin 123 Anastrozole 116 Surveys and Questionnaires 115 Exercise 109 Vinorelbine 99 palbociclib 91 exemestane 91 Blood Specimen Collection 91 Magnetic Resonance Spectroscopy 88 Bevacizumab 88 pembrolizumab 87 pertuzumab 85 Albumin-Bound Paclitaxel 76 Gemcitabine 73 Lapatinib 68 Drug Therapy 67 eribulin 62 Neoadjuvant Therapy 61 130-nm albumin-bound paclitaxel 61

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02590315 2019-01-31

ProteusDonna

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Phase 4 Unknown

92,000 enrolled

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡